There are currently no approved therapies for sarcopenia, the age-related loss of skeletal muscle mass and strength. This Review discusses advances in understanding of the cellular, molecular and metabolic mechanisms driving muscle wasting with ageing, while assessing emerging therapeutic approaches and agents in development.